Cargando…
Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation
OBJECTIVE: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-reject...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598712/ https://www.ncbi.nlm.nih.gov/pubmed/37885888 http://dx.doi.org/10.3389/fimmu.2023.1263389 |
_version_ | 1785125614983839744 |
---|---|
author | Li, Yunhui Liang, Bin |
author_facet | Li, Yunhui Liang, Bin |
author_sort | Li, Yunhui |
collection | PubMed |
description | OBJECTIVE: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation. METHODS: A systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection. RESULTS: The results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I(2 =) 88.6%, P< 0.001; ACR: SMD=1.03, 95% CI: 0.47-1.59, I(2 =) 89.0%, P < 0.001; AMR: SMD= 1.78, 95% CI: 1.20-2.35, I(2 =) 89.8%, P < 0.001). Circulating dd-cfDNA levels distinguished graft rejection from non-rejection with a pooled sensitivity of 0.87 (95% CI: 0.80-0.92) and a pooled specificity of 0.82 (95% CI: 0.76-0.86). The corresponding SROC yield an AUROC of 0.90 (95% CI: 0.87-0.93). CONCLUSION: Circulating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023440467. |
format | Online Article Text |
id | pubmed-10598712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105987122023-10-26 Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation Li, Yunhui Liang, Bin Front Immunol Immunology OBJECTIVE: Recently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation. METHODS: A systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection. RESULTS: The results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I(2 =) 88.6%, P< 0.001; ACR: SMD=1.03, 95% CI: 0.47-1.59, I(2 =) 89.0%, P < 0.001; AMR: SMD= 1.78, 95% CI: 1.20-2.35, I(2 =) 89.8%, P < 0.001). Circulating dd-cfDNA levels distinguished graft rejection from non-rejection with a pooled sensitivity of 0.87 (95% CI: 0.80-0.92) and a pooled specificity of 0.82 (95% CI: 0.76-0.86). The corresponding SROC yield an AUROC of 0.90 (95% CI: 0.87-0.93). CONCLUSION: Circulating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD42023440467. Frontiers Media S.A. 2023-10-11 /pmc/articles/PMC10598712/ /pubmed/37885888 http://dx.doi.org/10.3389/fimmu.2023.1263389 Text en Copyright © 2023 Li and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Yunhui Liang, Bin Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation |
title | Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation |
title_full | Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation |
title_fullStr | Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation |
title_full_unstemmed | Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation |
title_short | Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation |
title_sort | circulating donor-derived cell-free dna as a marker for rejection after lung transplantation |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598712/ https://www.ncbi.nlm.nih.gov/pubmed/37885888 http://dx.doi.org/10.3389/fimmu.2023.1263389 |
work_keys_str_mv | AT liyunhui circulatingdonorderivedcellfreednaasamarkerforrejectionafterlungtransplantation AT liangbin circulatingdonorderivedcellfreednaasamarkerforrejectionafterlungtransplantation |